Home » Stocks » SPHS

Sophiris Bio Inc. (SPHS)

Stock Price: $0.0293 USD -0.0027 (-8.44%)
Updated Feb 26, 2021 3:55 PM EST - Market closed
Market Cap 899,721
Revenue (ttm) n/a
Net Income (ttm) 37,000
Shares Out 32.07M
EPS (ttm) 0.00
PE Ratio 29.30
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day February 26
Last Price $0.0293
Previous Close $0.0320
Change ($) -0.0027
Change (%) -8.44%
Day's Open 0.0234
Day's Range 0.0234 - 0.0390
Day's Volume 338,204
52-Week Range 0.0035 - 0.72

News

GlobeNewsWire - 11 months ago

SAN DIEGO and VANCOUVER, British Columbia, March 10, 2020 (GLOBE NEWSWIRE) -- Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company studying topsalysin ...

About SPHS

Sophiris Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development of products for the treatment of urological diseases. The company's primary product candidate is PRX302 (topsalysin), which is in Phase III clinical trial for treatment of lower urinary tract symptoms of benign prostatic hyperplasia (BPH), as well as for the treatment of localized low to intermediate risk prostate cancer. It has a strategic relationship with Kissei Pharmaceutical Company for the development and commercialization of PRX302 for the treatmen... [Read more...]

Industry
Biotechnology
Founded
2002
CEO
Randall E. Woods
Employees
6
Stock Exchange
OTCMKTS
Ticker Symbol
SPHS
Full Company Profile

Financial Performance

Financial Statements